Early Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of blood cancer called CD5-positive T-cell non-Hodgkin lymphoma (T-NHL), confirmed by a tissue test and classified according to 2016 WHO guidelines
- People whose cancer has either not responded to treatment, has come back after at least two rounds of chemotherapy, was resistant to treatment from the beginning, or has returned after a bone marrow stem cell transplant using their own cells
- People whose cancer cells show a CD5 protein expression rate of more than 90%
- People who have at least one measurable tumour that can be tracked during the trial
- People whose liver function test results are within acceptable ranges (confirm with trial site for exact values)
- People whose heart is pumping blood effectively, with a heart pump function score of 50% or higher on an ultrasound test
- People whose blood oxygen levels are at 92% or above
- People with an estimated life expectancy of at least 12 weeks
- People who are reasonably well and able to carry out daily activities, rated 0–2 on a standard medical fitness scale (ECOG scale)
- People who are pregnant, breastfeeding, or able to have children and who are willing to use effective contraception during the study and for at least 6 months after the last treatment
- People who are willing to take part and have given their written informed consent
Who may not be able to join:
- People with a history of epilepsy or other conditions affecting the brain or nervous system
- People whose heart test (ECG) shows a prolonged QT interval, or who have a history of serious heart rhythm problems or other severe heart conditions
- People with an active hepatitis B, hepatitis C, or hepatitis E infection
- People who have an active infection that has not been successfully treated
- People who have previously received any gene therapy treatment
- People who have received certain treatments too recently before the cell infusion, including: high-dose steroid medicines within 72 hours, targeted therapy medicines within 72 hours, systemic chemotherapy within 2 weeks (except preparatory treatment), or radiotherapy within 4 weeks
- People whose immune cells do not respond strongly enough to a specific laboratory stimulation test (confirm with trial site for details)
- People whom the trial investigators consider unsuitable for any reason
- People in any situation that the trial investigators believe could increase risk or affect the reliability of the trial results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: He Huang, MD, First Affiliated Hospital of Zhejiang University
Phone: 057187233772
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Incidence of treatment-emergent adverse events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.